Scarica l'app Stockscreener
5.23
0.19%
0.01
Immuneering Corp Borsa (IMRX) Ultime notizie
Empery Asset Management, LP Reduces Stake in Immuneering Corp - GuruFocus
Thomas Schall Buys 21,645 Shares of Immuneering (NASDAQ:IMRX) Stock - Defense World
Immuneering (NASDAQ:IMRX) Insider Harold Eugene Brakewood Purchases 5,250 Shares of Stock - MarketBeat
Immuneering’s (IMRX) chief business officer buys $24,990 in stock By Investing.com - Investing.com Australia
Immuneering’s (IMRX) chief business officer buys $24,990 in stock - Investing.com
Insider Buying: Immuneering (NASDAQ:IMRX) Director Purchases 21,645 Shares of Stock - MarketBeat
Immuneering director Schall buys $101k in shares By Investing.com - Investing.com India
Immuneering director Schall buys $101k in shares - Investing.com
Immuneering Corporation (NASDAQ:IMRX) Short Interest Update - Defense World
Immuneering Corporation (NASDAQ:IMRX) Sees Significant Growth in Short Interest - MarketBeat
Insider Buying: Brett Hall Acquires Additional Shares of Immunee - GuruFocus
Hedge Fund and Insider Trading News: Ken Griffin, Bill Ackman, Michael Burry, Warren Buffett, Aurelius Capital Management, Balyasny Asset Management, Jain Global, Saba Capital Management, Bain Capital, Immuneering Corp (IMRX), Cloudflare Inc (NET) - Insider Monkey
Director of Immuneering Picks Up 1.8% More Stock - Yahoo Finance
Immuneering Director Acquires 1.8% More Stock - Sahm
Insider Buying: Leah Neufeld Acquires Additional Shares of Immuneering Corp (IMRX) - GuruFocus
Immuneering chief people officer Neufeld buys $10,905 in IMRX By Investing.com - Investing.com Nigeria
Immuneering chief people officer Neufeld buys $10,905 in IMRX - Investing.com
Looking Into Immuneering Corp's Recent Short Interest - Sahm
Immuneering director Feinberg buys $86k in shares By Investing.com - Investing.com Nigeria
Immuneering director Feinberg buys $86k in shares - Investing.com
Iridian Asset Management LLC CT Makes New $1.93 Million Investment in Immuneering Corporation $IMRX - MarketBeat
Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition - Yahoo Finance
Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next - Yahoo Finance
Why Immuneering (IMRX) Is Down 29.7% After Phase 2a Pancreatic Data Versus Historical Benchmarks And Phase 3 Plan - simplywall.st
Assessing Immuneering (IMRX) Valuation After Positive Phase 2a Pancreatic Cancer Trial Progress - simplywall.st
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - Sahm
Risk Hedge: Can Immuneering Corporation stock deliver strong Q4 earningsJuly 2025 Big Picture & Safe Capital Allocation Plans - ulpravda.ru
Can Immuneering Corporation stock outperform in 2025 bull marketJuly 2025 Momentum & Free Technical Pattern Based Buy Signals - ulpravda.ru
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data (NASDAQ:IMRX) - Seeking Alpha
Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink - TipRanks
Stock market today: S&P 500, Dow Jones futures decline — AZZ, Northrop Grumman, Immuneering in focus - MSN
Is Immuneering Corporation stock gaining market shareJuly 2025 Fed Impact & Community Trade Idea Sharing Platform - Улправда
IMRX Stock Closed Over 20% Higher Today: Here’s Why - Asianet Newsable
Immuneering Pancreatic Cancer Study Reports Promising Survival Results, Yet Shares Decline - Bitget
Why Is Immuneering Stock Trading Lower Today?Immuneering (NASDAQ:IMRX) - Benzinga
Immuneering: Phase 2a Strength of Atebimetinib in First-Line Pancreatic Cancer Supports Buy Rating Despite Competitive Overhang - TipRanks
Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update - TechStock²
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED) - Benzinga
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED) - Benzinga
Stock Market Update: S&P 500 and Dow Jones Futures Fall — Spotlight on AZZ, Northrop Grumman, Immuneering - Bitget
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - markets.businessinsider.com
IMRX Reports 12-Month Survival Of 64% In First-Line Pancreatic Cancer Patients; But Stock Plunges - RTTNews
Immuneering Highlights 64% 12-Month Survival in Phase 2A Pancreatic Cancer Study, Eyes Phase 3 - Yahoo Finance
IMRX: Atebumetanib plus chemo showed 64% 12-month survival in pancreatic cancer, nearly double standard care - TradingView — Track All Markets
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):